Evelo Biosciences, a clinical-stage biotech firm headquartered in Cambridge, Massachusetts, is dedicated to developing oral medicines that have systemic effects by targeting immune cells in the small intestine. At the forefront of their pipeline is EDP1815, a whole-microbe medication candidate targeting the treatment of psoriasis, which has completed Phase 2 trials. Additionally, EDP1815 is now undergoing Phase 2 clinical trials for treating atopic dermatitis. The company also has several other drugs in development, including EDP1867, a non-live pharmaceutical formulated for a single strain of Veillonella parvula, now going through Phase 1b trials; EDP2939, an oral biologic designed to tackle inflammatory diseases in humans, remains in investigational phases; and EDP1908, a candidate for treating cancer. Evelo Biosciences, founded in 2014, is urgently striving to advance the treatment of severe and debilitating diseases.